通过REVERSIRIR对抗抗 angiotensinogen 小干扰RNA介导的抗高血压作用
Dien Ye1, Edwyn O Cruz-López1, Richard van Veghel1
1Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands (D.Y., E.O.C.-L., R.v.V., I.M.G., A.H.J.D.).
Hypertension (Dallas, Tex. : 1979)
|May 1, 2024
概括
反向siRNA沉默技术 (RVR) 在老鼠中有效地逆转了由血管增生素 (AGT) siRNA引起的血压降低. 当需要时,这种技术提供了一种快速恢复血压的方法.
科学领域:
- 心血管研究研究心血管研究
- 基因沉默技术是一种技术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 小干扰RNA (siRNA) 向肝血管增生素 (AGT),可以长时间降低血压.
- 可能会出现需要快速增加血管素水平的情况.
- 反向siRNA沉默技术 (RVR) 提供了一种抵消siRNA效应的方法.
研究的目的:
- 评估RVR在逆转AGTsiRNA诱导的低血压方面的疗效.
- 为了确定AGT-RVR对血压和AGT水平的剂量依赖性影响.
- 评估AGT-RVR对随后的AGTsiRNA疗效以及与瓦尔萨坦结合的影响.
主要方法:
- 自发高血压的老鼠接受了AGTsiRNA治疗,随后以不同剂量的AGT-RVR治疗.
- 监测了血压,AGT水平和蛋白活性.
- 在AGT-RVR治疗后,评估了第二次AGT siRNA剂量的有效性.
- 研究了AGT-RVR和瓦尔沙坦之间的相互作用.
主要成果:
- AGT siRNA显著降低了平均动脉压 (MAP) 和AGT水平,增加了蛋白.
- 所有的AGT-RVR剂量在4-7天内使MAP正常化.
- 较高的AGT-RVR剂量使AGT和蛋白恢复到基线;较低的剂量允许部分恢复AGT.
- 随后的AGT siRNA治疗显示,在AGT-RVR给药后,疗效降低.
- AGT-RVR没有影响瓦尔萨坦诱导的MAP减少.
结论:
- 在大鼠中,依赖于剂量的angiotensinogen-RVR逆转了AGT siRNA诱导的低血压.
- 即使在部分AGT恢复的情况下,MAP正常化也持续,这表明蛋白的作用.
- 该RVR技术允许控制逆转siRNA介导的基因沉默效应.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
606
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
606
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
716
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
716
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
621
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
621
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
799
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
799
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
156
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
156